IL293342B1 - Using cell-free nucleosomes as biomarkers - Google Patents
Using cell-free nucleosomes as biomarkersInfo
- Publication number
- IL293342B1 IL293342B1 IL293342A IL29334222A IL293342B1 IL 293342 B1 IL293342 B1 IL 293342B1 IL 293342 A IL293342 A IL 293342A IL 29334222 A IL29334222 A IL 29334222A IL 293342 B1 IL293342 B1 IL 293342B1
- Authority
- IL
- Israel
- Prior art keywords
- subject
- cancer
- cell free
- vascular
- histone
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962942596P | 2019-12-02 | 2019-12-02 | |
| US202063088408P | 2020-10-06 | 2020-10-06 | |
| PCT/EP2020/084328 WO2021110776A1 (en) | 2019-12-02 | 2020-12-02 | Use of cell free nucleosomes as biomarkers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL293342A IL293342A (en) | 2022-07-01 |
| IL293342B1 true IL293342B1 (en) | 2026-01-01 |
Family
ID=73698838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL293342A IL293342B1 (en) | 2019-12-02 | 2020-12-02 | Using cell-free nucleosomes as biomarkers |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230003735A1 (https=) |
| EP (2) | EP4435431A3 (https=) |
| JP (2) | JP7693670B2 (https=) |
| KR (1) | KR102930652B1 (https=) |
| CN (1) | CN114829939B (https=) |
| AU (1) | AU2020395504A1 (https=) |
| BR (1) | BR112022010774A2 (https=) |
| CA (1) | CA3163181A1 (https=) |
| ES (1) | ES2988371T3 (https=) |
| IL (1) | IL293342B1 (https=) |
| MX (1) | MX2022006655A (https=) |
| PL (1) | PL4070111T3 (https=) |
| TW (1) | TWI902730B (https=) |
| WO (1) | WO2021110776A1 (https=) |
| ZA (1) | ZA202205916B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2820129A1 (en) * | 2012-03-02 | 2015-01-07 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| EP3736344A1 (en) | 2014-03-13 | 2020-11-11 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| JP2024542996A (ja) | 2021-10-29 | 2024-11-19 | ベルジアン ボリション エスアールエル | 均一系免疫アッセイ法 |
| GB202117799D0 (en) | 2021-12-09 | 2022-01-26 | Belgian Volition Srl | Method for the detection of blood cancer |
| EP4490323A1 (en) | 2022-03-11 | 2025-01-15 | Belgian Volition SRL | Differential diagnosis method |
| WO2024042210A1 (en) | 2022-08-25 | 2024-02-29 | Belgian Volition Srl | Method for measuring cell free chromatin |
| EP4639173A1 (en) * | 2022-12-19 | 2025-10-29 | Belgian Volition SRL | Calibration |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2282208A1 (en) * | 2009-08-03 | 2011-02-09 | Universitätsklinikum Freiburg | Methods and compounds for the diagnosis and treatment of cancer |
| WO2013030578A2 (en) * | 2011-09-01 | 2013-03-07 | Singapore Volition Pte Limited | Method for detecting nucleosomes |
| WO2013084002A2 (en) * | 2011-12-07 | 2013-06-13 | Singapore Volition Pte Limited | Method for detecting nucleosome adducts |
| US20130230858A1 (en) * | 2012-03-02 | 2013-09-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20140107039A1 (en) * | 2012-09-10 | 2014-04-17 | The Rockefeller University | Polycomb repressive complex 2 (prc2) inhibitors and uses thereof |
| WO2016067029A1 (en) * | 2014-10-29 | 2016-05-06 | Singapore Volition Pte Limited | Method for the enrichment of circulating tumor dna |
| WO2017001864A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in fecal samples |
| WO2017001863A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in sputum samples |
| WO2017068359A1 (en) * | 2015-10-21 | 2017-04-27 | Belgian Volition Sprl | Method for detecting nucleosomes containing histone modifications and variants |
| WO2019169263A1 (en) * | 2018-03-01 | 2019-09-06 | Epicypher, Inc. | Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0319376D0 (en) | 2003-08-18 | 2003-09-17 | Chroma Therapeutics Ltd | Histone modification detection |
| GB0413732D0 (en) * | 2004-06-13 | 2004-07-21 | Chroma Therapeutics Ltd | Histone modification |
| GB201115098D0 (en) | 2011-09-01 | 2011-10-19 | Belgian Volition Sa | Method for detecting nucleosomes containing histone variants |
| GB201115095D0 (en) | 2011-09-01 | 2011-10-19 | Singapore Volition Pte Ltd | Method for detecting nucleosomes containing nucleotides |
| GB201518665D0 (en) * | 2015-10-21 | 2015-12-02 | Singapore Volition Pte Ltd | Method for enrichment of cell free nucleosomes |
-
2020
- 2020-12-02 IL IL293342A patent/IL293342B1/en unknown
- 2020-12-02 AU AU2020395504A patent/AU2020395504A1/en active Pending
- 2020-12-02 CN CN202080083887.9A patent/CN114829939B/zh active Active
- 2020-12-02 MX MX2022006655A patent/MX2022006655A/es unknown
- 2020-12-02 EP EP24193398.5A patent/EP4435431A3/en active Pending
- 2020-12-02 BR BR112022010774A patent/BR112022010774A2/pt unknown
- 2020-12-02 CA CA3163181A patent/CA3163181A1/en active Pending
- 2020-12-02 US US17/781,652 patent/US20230003735A1/en active Pending
- 2020-12-02 PL PL20819704.6T patent/PL4070111T3/pl unknown
- 2020-12-02 TW TW109142306A patent/TWI902730B/zh active
- 2020-12-02 EP EP20819704.6A patent/EP4070111B1/en active Active
- 2020-12-02 ES ES20819704T patent/ES2988371T3/es active Active
- 2020-12-02 WO PCT/EP2020/084328 patent/WO2021110776A1/en not_active Ceased
- 2020-12-02 JP JP2022532782A patent/JP7693670B2/ja active Active
- 2020-12-02 KR KR1020227022609A patent/KR102930652B1/ko active Active
-
2022
- 2022-05-27 ZA ZA2022/05916A patent/ZA202205916B/en unknown
-
2025
- 2025-06-05 JP JP2025093848A patent/JP2025124845A/ja active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2282208A1 (en) * | 2009-08-03 | 2011-02-09 | Universitätsklinikum Freiburg | Methods and compounds for the diagnosis and treatment of cancer |
| WO2013030578A2 (en) * | 2011-09-01 | 2013-03-07 | Singapore Volition Pte Limited | Method for detecting nucleosomes |
| WO2013084002A2 (en) * | 2011-12-07 | 2013-06-13 | Singapore Volition Pte Limited | Method for detecting nucleosome adducts |
| US20130230858A1 (en) * | 2012-03-02 | 2013-09-05 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US20140107039A1 (en) * | 2012-09-10 | 2014-04-17 | The Rockefeller University | Polycomb repressive complex 2 (prc2) inhibitors and uses thereof |
| WO2016067029A1 (en) * | 2014-10-29 | 2016-05-06 | Singapore Volition Pte Limited | Method for the enrichment of circulating tumor dna |
| WO2017001864A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in fecal samples |
| WO2017001863A1 (en) * | 2015-07-01 | 2017-01-05 | Singapore Volition Pte. Limited | Use of cell-free nucleosomes as biomarkers in sputum samples |
| WO2017068359A1 (en) * | 2015-10-21 | 2017-04-27 | Belgian Volition Sprl | Method for detecting nucleosomes containing histone modifications and variants |
| WO2019169263A1 (en) * | 2018-03-01 | 2019-09-06 | Epicypher, Inc. | Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes |
Non-Patent Citations (6)
| Title |
|---|
| BOHENG LI ET AL,, EZH2 ABNORMALITIES IN LYMPHOIDMALIGNANCIES: UNDERLYING MECHANISMS ANDTHERAPEUTIC IMPLICATIONS, 21 November 2019 (2019-11-21) * |
| HEIDI SCHWARZENBACH ET AL,, CELL-FREE NUCLEIC ACIDS AS BIOMARKERS IN CANCER PATIENTS, 31 December 2011 (2011-12-31) * |
| HERRANZ MICHEL ET AL,, DNA METHYLATION AND HISTONE MODIFICATIONS IN PATIENTS WITH CANCER: POTENTIAL PROGNOSTIC AND THERAPEUTIC TARGETS, 31 December 2007 (2007-12-31) * |
| M. T. MCCABE ET AL,, MUTATION OF A677 IN HISTONE METHYLTRANSFERASE EZH2 IN HUMAN B-CELL LYMPHOMA PROMOTES HYPERTRIMETHYLATION OF HISTONE H3 ON LYSINE 27 (H3K27), 31 December 2012 (2012-12-31) * |
| STEFAN HOLDENRIEDER ET AL,, CLINICAL RELEVANCE OF CIRCULATING NUCLEOSOMES IN CANCER, 31 December 2008 (2008-12-31) * |
| STEFAN HOLDENRIEDER ET AL,, NUCLEOSOMES IN SERUM OF PATIENTS WITH BENIGN AND MALIGNANT DISEASES, 31 December 2001 (2001-12-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4070111A1 (en) | 2022-10-12 |
| MX2022006655A (es) | 2022-09-07 |
| KR102930652B1 (ko) | 2026-02-25 |
| TW202134654A (zh) | 2021-09-16 |
| AU2020395504A1 (en) | 2022-06-23 |
| ES2988371T3 (es) | 2024-11-20 |
| JP7693670B2 (ja) | 2025-06-17 |
| CA3163181A1 (en) | 2021-06-10 |
| US20230003735A1 (en) | 2023-01-05 |
| EP4070111B1 (en) | 2024-08-21 |
| BR112022010774A2 (pt) | 2022-08-23 |
| KR20220110794A (ko) | 2022-08-09 |
| JP2025124845A (ja) | 2025-08-26 |
| JP2023503379A (ja) | 2023-01-27 |
| PL4070111T3 (pl) | 2025-02-03 |
| EP4435431A3 (en) | 2024-10-16 |
| EP4435431A2 (en) | 2024-09-25 |
| CN114829939B (zh) | 2025-10-21 |
| CN114829939A (zh) | 2022-07-29 |
| IL293342A (en) | 2022-07-01 |
| WO2021110776A1 (en) | 2021-06-10 |
| TWI902730B (zh) | 2025-11-01 |
| ZA202205916B (en) | 2024-09-25 |
| EP4070111C0 (en) | 2024-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4070111B1 (en) | Use of cell free nucleosomes as biomarkers | |
| US20240019432A1 (en) | Diagnostic method for multiple sclerosis | |
| EP3963330B1 (en) | Method for the detection of prostate cancer | |
| US20200182875A1 (en) | Combination test for colorectal cancer | |
| US20240077487A1 (en) | Method for the detection of lung cancer | |
| HK40085725B (en) | Use of cell free nucleosomes as biomarkers | |
| HK40085725A (en) | Use of cell free nucleosomes as biomarkers | |
| EP3963331B1 (en) | Method for the detection of cancer | |
| EA047224B1 (ru) | Применение бесклеточных нуклеосом в качестве биомаркеров | |
| EP4720677A1 (en) | Use of cell free nucleosomes as biomarkers | |
| WO2024223947A1 (en) | Use of cell free nucleosomes as biomarkers of carcinomas | |
| US20250044291A1 (en) | Method for the detection of blood cancer | |
| WO2025008388A1 (en) | Method for the detection of cancer |